Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | HTR2B | P41595 | 3/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 3/20 | 0.37 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | HTR6 | P50406 | 3/20 | 0.37 |
| ▸ | SCN1A | P35498 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13077344 | 0.90 | TSHR (0.40) | NR2E1TSHRALDH1A1KDM4EMEN1 | |
| SCHEMBL13149083 | 0.82 | NR2E1 (0.61) | NR2E1TSHRALDH1A1KDM4EKMT2A | |
| SCHEMBL13149112 | 0.82 | NR2E1 (0.61) | NR2E1TSHRALDH1A1KDM4EKMT2A | |
| SCHEMBL13077481 | 0.76 | NR2E1 (0.47) | NR2E1TSHRALDH1A1KDM4EMEN1 | |
| SCHEMBL13077524 | 0.76 | HTR1A (0.43) | TSHRALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL13077340 | 0.76 | NR2E1 (0.39) | NR2E1TSHRALDH1A1KMT2ACYP2D6 | |
| SCHEMBL9330203 | 0.75 | NR2E1 (0.50) | NR2E1TSHRALDH1A1KDM4EMEN1 | |
| SCHEMBL9332855 | 0.75 | NR2E1 (0.46) | NR2E1TSHRALDH1A1KDM4EMEN1 | |
| SCHEMBL14571129 | 0.74 | HTR1A (0.41) | TSHRALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL13040039 | 0.74 | NR2E1 (0.37) | NR2E1TSHRALDH1A1KMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251959-B2 | Oligomer-beta blocker conjugates | NEKTAR THERAPEUTICS (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170360948-A1 | OLIGOMER-BETA BLOCKER CONJUGATES | NEKTAR THERAPEUTICS | 2017-12-21 | — | — | US | disclosed |
| US-20170360948-A1 | OLIGOMER-BETA BLOCKER CONJUGATES | NEKTAR THERAPEUTICS | 2017-12-21 | — | — | US | disclosed |
| US-9782488-B2 | Oligomer-beta blocker conjugates | NEKTAR THERAPEUTICS (US) | 2017-10-10 | — | — | US | disclosed |
| US-9782488-B2 | Oligomer-beta blocker conjugates | NEKTAR THERAPEUTICS (US) | 2017-10-10 | — | — | US | disclosed |
| US-20100227865-A1 | Oligomer-Beta Blocker Conjugates | NEKTAR THERAPEUTICS | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251959-B2 | Oligomer-beta blocker conjugates | ADRB1, ADRB2, ADRA2B | NR2E1 3263/4885TSHR 2501/4885ALDH1A1 2337/4885 |
| US-20100227865-A1 | Oligomer-Beta Blocker Conjugates | ADRB1, ADRA2B, ADRB2 | NR2E1 3339/4885TSHR 2513/4885ALDH1A1 1827/4885 |
| US-20170360948-A1 | OLIGOMER-BETA BLOCKER CONJUGATES | ADRB1, ADRB2, ADRA2B | NR2E1 3263/4885TSHR 2501/4885ALDH1A1 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.